Loading
TQB2922 is an experimental bispecific antibody from Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical in phase 2 trials for colorectal cancer, aimed at EGFR and MET.
TQB2922 is a bispecific antibody developed by Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical. Its targets are EGFR and MET (the sponsor names EGFR x c-Met). The sponsor states: TQB2922 is an anti-EGFR/c-Met bispecific IgG1 antibody that blocks EGFR and c-Met signalling by binding both receptors on tumour cells and engages antibody-dependent cellular cytotoxicity and phagocytosis via NK cells and macrophages. ClinicalTrials.gov describes the intervention as: TQB2922 is an anti-EGFR/c-Met bispecific antibody, subtype Immunoglobulin G1 (IgG1). TQB2922 blocks the activation of EGFR and c-Met signalling pathway by binding to EGFR and c-Met on the surface of tumour cells, thus preventing tumour grow. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in colorectal cancer. The largest, NCT07044908, plans to enrol 72 participants with primary completion was scheduled for 2026-07 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
1.One arm of TQB2922 binds EGFR on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"TQB2922" OR ABSTRACT:"TQB2922") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TQB2922, not a curated reading list.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), MET, EGFR and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), MET and the tag pipeline.
Shares MET, Colorectal cancer and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), EGFR and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.